Dr. Mihae  Song  Md image

Dr. Mihae Song Md

125 Paterson St Cab 2100
New Brunswick NJ 08901
732 357-7643
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 25MA09284600
NPI: 1144665423
Taxonomy Codes:

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy


Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found


None Found


Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer. - Journal of personalized medicine
Classification of pediatric brain tumors with unusual histologic and clinical features may be a diagnostic challenge to the pathologist. We present a case of a 12-year-old girl with a primary intracranial tumor. The tumor classification was not certain initially, and the site of origin and clinical behavior were unusual. Genomic characterization of the tumor using a Clinical Laboratory Improvement Amendment (CLIA)-certified next-generation sequencing assay assisted in the diagnosis and translated into patient benefit, albeit transient. Our case argues that next generation sequencing may play a role in the pathological classification of pediatric brain cancers and guiding targeted therapy, supporting additional studies of genetically targeted therapeutics.
Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer. - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Overexpression of bcl-2 is a mechanism of drug resistance in cervical cancer. Agents that down-regulate bcl-2 may decrease tumor cell threshold and sensitize tumor cells to chemotherapy. The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer.Patients had biopsy-proven metastatic, first relapse, or persistent cervical cancer with no prior chemotherapy except for chemosensitizing agents. The treatment consisted of oral 13-cis retinoic acid, 1 mg/kg, and subcutaneous interferon alfa-2b, 6 mU/m, days 1 to 4, and intravenous paclitaxel, 175 mg/m, day 4 until disease progression or adverse events prohibited treatment. The primary endpoint was overall response rate.Thirty-three patients were enrolled between March 2001 and June 2009. Thirty-one patients were eligible for evaluation of treatment response. Twenty-seven patients (82%) received prior concurrent chemoradiation or radiotherapy alone before study enrollment. The overall response rate was 30% (6 complete responses and 4 partial responses). Furthermore, 7 patients (21%) had stable disease. Grade 3 or 4 adverse events included neutropenia (n =16 [48%]), febrile neutropenia (n = 1 [3%]), and anemia (n = 1 [3%]). There were no treatment-related deaths. The median progression-free survival was 3.4 months (95% confidence interval, 2.0-7.4 months), and overall survival was 11.2 months (95% confidence interval, 7.5-26.2 months). Of 6 patients with complete responses, 5 patients survived more than 2 years.Combination therapy with paclitaxel, 13-cis retinoic acid, and interferon alfa-2b is feasible and safe in treating patients with advanced and recurrent cervical cancer.

Map & Directions

125 Paterson St Cab 2100 New Brunswick, NJ 08901
View Directions In Google Maps

Nearby Doctors

17 Senior St
New Brunswick, NJ 08901
732 327-7884
240 Easton Ave
New Brunswick, NJ 08901
732 458-8564
195 Little Albany St
New Brunswick, NJ 08901
732 533-3939
1 Robert Wood Johnson Pl
New Brunswick, NJ 08901
732 378-8841
254 Easton Ave
New Brunswick, NJ 08901
732 458-8600
1 Robert Wood Johnson Pl Robert Wood Johnson University Hsptl - New Brunswick
New Brunswick, NJ 08901
732 357-7044
1 Robert Wood Johnson Pl Department Of Emergency Medicine
New Brunswick, NJ 08901
732 283-3000
125 Paterson St Clinical Academic Building - Suite 5200A
New Brunswick, NJ 08901
732 357-7217